title: Health and quality of life in patients with relapsing multiple sclerosis: making the intangible tangible.
abstract: Multiple sclerosis is diagnosed primarily in young adults with aspirations for both family and careers. For this reason, it is important to take into account the potential impact of disease and treatment on these aspirations, which relate to quality of life. Quality of life evaluations and measurements have now become an integral part of comprehensive care for multiple sclerosis patients. Moreover, quality of life endpoints are now included in most therapeutic trials of potential new treatments, as well as in observational studies of the management of multiple sclerosis. The scope of quality of life includes self-perceived status in three important domains of life, namely physical (e.g. disability, strength), psychological (e.g. depression, fatigue) and social functioning (e.g. employment, usual daily activities). A number of studies have demonstrated a positive impact on quality of life of treatment with glatiramer acetate in the above areas. Several of these included direct comparisons between glatiramer acetate and interferon-beta. it is important that quality of life issues are addressed at the outset by patients and professionals, and taken into account when choosing the most appropriate therapy for a given individual.
authors.affiliation: Baptist Health Comprehensive Care Multiple Sclerosis Center, Coral Gables, FL 33146, USA. zwibelmdms@aol.com
authors.forename: Howard
authors.initials: H
authors.lastname: Zwibel
mesh_terms: D003863:Depression / Q000188:drug therapy / Q000523:psychology; D005221:Fatigue / Q000188:drug therapy / Q000523:psychology; D000068717:Glatiramer Acetate; D006304:Health Status; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000523:psychology*; D010455:Peptides / Q000627:therapeutic use; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta